Skip to main content

Table 1 Blood test schedule following treatment with I131 KAb201

From: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

Blood test Time points
Haematology Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Biochemistry Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Pharmacokinetics and radioactivity levels Days 1, 2, 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
HASA/HACA Days 14, 28, 42, 60 and 90 post treatment
Serum CEA/CA19-9 Days 28, 60 and 90 post treatment
CEA complexing assay 6 hours post dosimetry
  1. HASA = Human antisheep antibody; HACA = Human anti-chimaeric antibody; CEA = Carcino-Embryonic antigen